Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 16/20 | 0.61 |
| ▸ | GRM4 | Q14833 | 16/20 | 0.61 |
| ▸ | GRM6 | O15303 | 10/20 | 0.61 |
| ▸ | GRM7 | Q14831 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.44 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.44 |
| ▸ | KYNU | Q16719 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10000468 | 0.93 | GRM8 (0.61) | GRM8GRM4GRM6GRM7KDM4E | |
| SCHEMBL346474 | 0.92 | GRM8 (0.51) | GRM8GRM4GRM6GRM7KDM4E | |
| SCHEMBL346473 | 0.92 | GRM8 (0.51) | GRM8GRM4GRM6GRM7KDM4E | |
| SCHEMBL10000469 | 0.92 | GRM8 (0.55) | GRM8GRM4GRM6GRM7KDM4E | |
| SCHEMBL8240661 | 0.90 | GRM8 (0.61) | GRM8GRM4GRM6GRM7MEN1 | |
| SCHEMBL8238396 | 0.88 | GRM8 (0.56) | GRM8GRM4GRM6GRM7GSTP1 | |
| SCHEMBL4085127 | 0.86 | GRM8 (0.58) | GRM8GRM4GRM6GRM7ALDH1A1 | |
| SCHEMBL16460538 | 0.86 | GRM8 (0.45) | GRM8GRM4GRM6GRM7KDM4E | |
| SCHEMBL13774905 | 0.86 | GRM8 (0.52) | GRM8GRM4GRM6ALDH1A1GSTP1 | |
| SCHEMBL13774887 | 0.85 | GRM8 (0.57) | GRM8GRM4GRM6GRM7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016155-A1 | DIASTEREOISOMERS OF HYPOPHOSPHOROUS ACID DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-01-19 | — | — | US | disclosed |
| US-20120016155-A1 | DIASTEREOISOMERS OF HYPOPHOSPHOROUS ACID DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-01-19 | — | — | US | disclosed |
| WO-2010106526-A1 | DIASTEREOISOMERS OF HYPOPHOSPHOROUS ACID DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-09-23 | — | — | WO | disclosed |
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2009-07-02 | — | — | US | disclosed |
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | P4HA1, CYP2R1, EGLN3 | GRM8 1667/4885GRM4 1497/4885GRM6 1170/4885 |
| US-20120016155-A1 | DIASTEREOISOMERS OF HYPOPHOSPHOROUS ACID DERIVATIVES | PTH1R, P4HA1, FGF23 | GRM8 4160/4885GRM4 3644/4885GRM6 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.